XML 20 R2.htm IDEA: XBRL DOCUMENT v3.2.0.727
Condensed Consolidated Balance Sheets (Unaudited) - USD ($)
$ in Thousands
Jun. 30, 2015
Dec. 31, 2014
Current assets:    
Cash and cash equivalents $ 20,875 $ 12,365
Restricted cash 25,000 25,000
Short-term investments 233,785 225,459
Accounts receivable, net 3,680 3,607
Inventory 10,124 12,952
Other current assets 8,782 8,817
Total current assets 302,246 288,200
Property, plant and equipment, net 72,158 70,368
Goodwill 76,501 76,501
Other assets 5,762 6,552
Total assets 456,667 441,621
Current liabilities:    
Accounts payable 2,833 2,703
Accrued compensation 10,824 5,749
Accrued clinical trial expenses 8,946 7,708
Other accrued expenses 9,713 6,418
Interest payable 6,917 6,917
Capital lease obligations, current portion 5,643 4,512
Deferred revenue, current portion 22,987 24,473
Other current liabilities 13,214 5,567
Total current liabilities 81,077 64,047
Senior secured notes 125,000 125,000
Capital lease obligations, less current portion 2,889 4,139
Liability related to sale of future royalties 121,971 120,471
Deferred revenue, less current portion 73,963 76,911
Other long-term liabilities 16,668 14,721
Total liabilities $ 421,568 $ 405,289
Commitments and contingencies    
Stockholders' equity:    
Preferred stock, $0.0001 par value, 10,000 shares authorized, no shares designated, issued or outstanding at June 30, 2015 or December 31, 2014 $ 0 $ 0
Common stock, $0.0001 par value, 300,000 authorized; 132,185 shares and 131,216 shares issued and outstanding at June 30, 2015 and December 31, 2014, respectively 13 13
Capital in excess of par value 1,841,730 1,824,195
Accumulated other comprehensive loss (1,498) (1,567)
Accumulated deficit (1,805,146) (1,786,309)
Total stockholders' equity 35,099 36,332
Total liabilities and stockholders' equity $ 456,667 $ 441,621